{"entity":{"id":"opp-fap-pancreatic-staging","kind":"opportunity","name":"FAP imaging to stop futile pancreatic surgery","aka":["FAPI PET in PDAC"],"tldr":"Four in ten pancreatic cancer patients whose scans say the tumour can be removed turn out, once opened up, to have disease that cannot be removed. A scan that lights up the scar tissue around tumour deposits sees more of that hidden disease than the standard one.","summary":"The number that defines this opportunity comes from a Cochrane review: the median pre-test probability of unresectable disease after CT was 41.4%, meaning 41 of 100 participants whose cancer looked resectable on CT were found unresectable at laparotomy. The operation that follows is major surgery with no curative benefit.\n\nFAP imaging attacks that gap directly, because pancreatic ductal adenocarcinoma is a stroma-rich tumour and the tracer reports the fibroblast compartment rather than glucose uptake. A 62-patient prospective study of 18F-FAPI-04 against FDG upgraded the TNM stage in 14 patients, with higher uptake in primary tumours, nodes, liver and peritoneal deposits, and FDG missed one patient with cancer that FAPI found. A PDAC-specific meta-analysis of 7 studies and 322 patients gives pooled sensitivity of 0.99 against 0.84 for FDG with comparable specificity. A 20-patient Korean study found FAPI-74 detected metastatic nodes in 50% of cases against 0% for FDG.\n\nThe gap in the evidence is precise and worth stating: no trial has yet reported that FAPI-based selection reduces the non-curative laparotomy rate. The completed SOFIE phase 2 (NCT05262855, 63 patients) measured sensitivity against histopathology, not operations avoided. On the therapy side the picture is discouraging — FRONTIER was terminated early for rapid clearance and low tumour doses, and across eight compassionate-use patients the predominant outcome was radiological progression — which strengthens the case for treating this as a diagnostic opportunity rather than a theranostic one.","asOf":"2026-09-23","links":[{"label":"Cochrane review: unresectable disease found at laparotomy after CT","url":"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.cd009323.pub3/full"},{"label":"18F-FAPI-04 against FDG in 62 patients, J Nucl Med 2024","url":"https://jnm.snmjournals.org/content/jnumed/65/2/206.full.pdf"},{"label":"NCT05262855: [68Ga]FAPI-46 phase 2 in pancreatic cancer","url":"https://clinicaltrials.gov/study/NCT05262855"},{"label":"[18F]AlF-FAPI-74 in potentially resectable pancreatic cancer","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11634952/"},{"label":"FRONTIER terminated early for rapid clearance","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12607575/"}],"tags":["unmet need first","pancreas","surgical selection","stroma"],"related":["ga-68","f-18","lu-177"],"indications":["pancreatic-cancer"],"sections":[],"technologies":["fapi-pet","pet-ct","fdg-pet"],"targets":["fap"],"drugs":["ga-68-fapi-46","fap-2286"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"lens":"unmet-need-first","unmetNeed":"No validated test tells a pancreatic tumour board, before operating, whether a CT-resectable tumour hides peritoneal or small liver metastases, and 41.4% of CT-resectable patients are found unresectable at laparotomy.","useCase":"A hepatobiliary surgeon and tumour board would scan every patient considered for resection or for neoadjuvant therapy, and would cancel or defer surgery on the strength of peritoneal or hepatic deposits that CT cannot see. The endpoint that matters is operations not performed.","hypothesis":"FAP-directed PET before pancreatic resection will identify CT-occult peritoneal and hepatic metastases often enough to reduce the non-curative laparotomy rate below the 41.4% that follows CT staging alone.","rationale":"Pancreatic ductal adenocarcinoma is defined by its fibroblast-rich stroma, which is why a tracer aimed at fibroblast activation protein has repeatedly outperformed FDG in this disease specifically: pooled sensitivity 0.99 against 0.84 across 322 patients, stage upgraded in 14 of 62 patients in a prospective head-to-head, and peritoneal disease visible where FDG showed nothing. Multiple isotopes and constructs work, including fluorine-18 versions that can be distributed. The missing step is not proof of detection but proof of consequence.","test":"A prospective study in patients deemed resectable on CT, imaging all of them with a FAP tracer, with a pre-specified rule for when a FAPI-positive extra-pancreatic finding cancels or alters surgery, and the primary endpoint being the non-curative laparotomy rate against the 41.4% historical benchmark. Histology or laparoscopy must confirm every scan-positive finding that changes management.","maturity":"being-tested-at-scale","verdict":"standalone-and-companion","mostAdvanced":"[68Ga]FAPI-46 from SOFIE: a completed prospective multicentre phase 2 in resectable or borderline resectable pancreatic ductal adenocarcinoma, 63 patients, with histopathology as truth standard (NCT05262855). On the therapy side, 177Lu-FAP-2286 in Novartis's LuMIERE phase 1/2 (NCT04939610).","dueDiligence":[{"domain":"target-biology","state":"strong","why":"Pancreatic ductal adenocarcinoma is stroma-rich and fibroblast activation protein is expressed in the tumour stroma rather than the tumour cells, which is why uptake exceeds FDG in primary tumours, nodes and peritoneal deposits.","source":"Wang et al., J Nucl Med 2024","url":"https://jnm.snmjournals.org/content/jnumed/65/2/206.full.pdf","weighted":true},{"domain":"clinical-evidence","state":"strong","why":"A completed prospective multicentre phase 2 of 63 patients with histopathology truth standard, a 62-patient prospective head-to-head against FDG, a 20-patient resectability cohort, and a PDAC-specific meta-analysis of 7 studies and 322 patients.","source":"NCT05262855 and Hu et al. meta-analysis","url":"https://clinicaltrials.gov/study/NCT05262855","weighted":true},{"domain":"diagnostic-performance","state":"strong","why":"Pooled sensitivity 0.99 (0.97 to 1.00) for FAPI against 0.84 (0.70 to 0.92) for FDG with comparable specificity across 322 patients; stage upgraded in 14 of 62 patients in a prospective comparison.","source":"PDAC-specific meta-analysis, Academic Radiology 2025","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12890629/","weighted":true},{"domain":"safety-dosimetry","state":"moderate","why":"Diagnostic FAPI agents have been used across many published cohorts without reported safety signals; on the therapeutic side whole-body effective dose for 177Lu-FAPI-XT was 0.039 plus or minus 0.013 Sv/GBq.","source":"Phase 1 dose escalation report","url":"https://pubmed.ncbi.nlm.nih.gov/41087606/"},{"domain":"regulatory-path","state":"thin","why":"No FAP imaging agent is approved anywhere, and no trial has yet used a management endpoint such as avoided laparotomy, which is the claim this opportunity actually needs.","source":"NCT05262855 primary outcome","url":"https://clinicaltrials.gov/study/NCT05262855"}],"flags":[{"category":"technical","flag":"green","why":"Works with both gallium-68 and fluorine-18 constructs, same-day imaging, and repeatedly reproduced across independent centres."},{"category":"unmet-need","flag":"green","why":"A 41.4% futile-laparotomy rate after CT staging is a large, quantified, guideline-recognised failure of current imaging."},{"category":"ip","flag":"red","why":"The FAPI chemical space is crowded with FAPI-04, FAPI-46, FAPI-74, FAP-2286 and numerous derivatives across multiple sponsors and academic groups."},{"category":"commercial","flag":"green","why":"Standalone: the value is surgery avoided, which needs no drug approval, and a FAP-directed therapy would be an additional rather than a necessary use."},{"category":"isotope","flag":"green","why":"Gallium-68 and fluorine-18 both established; the therapeutic side would need lutetium-177 or an alpha emitter."},{"category":"competition","flag":"red","why":"A completed multicentre phase 2 exists, Novartis holds the leading therapeutic, and numerous academic groups publish in this space."}],"competition":[{"name":"SOFIE Biosciences","what":"[68Ga]FAPI-46 phase 2 in resectable and borderline resectable pancreatic ductal adenocarcinoma, 63 patients, completed, histopathology truth standard.","stage":"phase 2 complete","url":"https://clinicaltrials.gov/study/NCT05262855"},{"name":"Novartis","what":"177Lu-FAP-2286 in LuMIERE, phase 1/2, 222 planned; phase 1 had 27 patients including 9 with pancreatic cancer, with one partial response and nine stable.","stage":"phase 1/2","url":"https://clinicaltrials.gov/study/NCT04939610"},{"name":"Chinese and Korean academic groups","what":"18F-FAPI-04 in 62 patients prospectively against FDG, and [18F]AlF-FAPI-74 in 20 potentially resectable patients.","stage":"published prospective studies","url":"https://jnm.snmjournals.org/content/jnumed/65/2/206.full.pdf"},{"name":"POINT Biopharma","what":"177Lu-PNT6555 in FRONTIER, terminated early because rapid clearance gave low tumour absorbed doses and limited efficacy.","stage":"terminated","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12607575/"}],"differentiation":"The comparators are CT, which leaves a 41.4% futile-laparotomy rate, and staging laparoscopy, which is itself an operation. CA 19-9 is neither sensitive nor specific enough to decide resectability, and FDG PET is not standard in this disease. FAP imaging is differentiated because pancreatic cancer is the tumour where the stromal target is most abundant and FDG performs worst.","metrics":[{"label":"CT-resectable patients found unresectable at laparotomy","value":"41.4% median pre-test probability","source":"Cochrane review, Allen et al. 2016","url":"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.cd009323.pub3/full"},{"label":"Pooled sensitivity of FAPI against FDG in pancreatic ductal adenocarcinoma","value":"0.99 against 0.84 across 7 studies and 322 patients","source":"Hu et al., Academic Radiology 2025, via review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12890629/"},{"label":"Patients whose TNM stage was upgraded by 18F-FAPI-04 against FDG","value":"14 of 62","source":"Wang et al., J Nucl Med 2024","url":"https://jnm.snmjournals.org/content/jnumed/65/2/206.full.pdf"},{"label":"Metastatic lymph node detection, FAPI-74 against FDG","value":"50% against 0% of 10","source":"20-patient prospective cohort","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11634952/"}],"risks":["FAP is expressed in wound healing, pancreatitis and other fibrotic conditions, so specificity in a chronically inflamed pancreas is the obvious failure mode and needs its own dataset.","Detection superiority does not automatically translate into fewer futile operations; a surgeon will not cancel an operation on an unbiopsied peritoneal signal without prospective evidence.","The therapeutic side of FAP is going badly, with one terminated trial and mostly progression in compassionate use, so a theranostic pitch would be weak."],"watch":["Publication of the SOFIE phase 2 results and whether any follow-on trial adopts avoided laparotomy as an endpoint.","Specificity data in chronic pancreatitis and post-treatment fibrosis, which is where this agent will either hold up or fail.","Whether FAP-directed therapy recovers after FRONTIER, which determines if a companion use ever exists."]},"route":"/opportunities/opp-fap-pancreatic-staging/","neighbours":{"isotope":[{"id":"f-18","kind":"isotope","name":"Fluorine-18","route":"/isotopes/f-18/"},{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/"},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}],"indication":[{"id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/"}],"technology":[{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/"},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/"}],"target":[{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/"}],"drug":[{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/"},{"id":"ga-68-fapi-46","kind":"drug","name":"Gallium-68 FAPI-46","route":"/drugs/ga-68-fapi-46/"}]}}